SCHEMBL16615814

SCHEMBL16615814

Cc1ncc(CNC(=O)c2cnc(CNC(=O)c3ccc(Cl)c(Cl)c3)cn2)s1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2A Q12879 3/20 0.61
GRIN1 Q05586 2/20 0.61
KMT2A Q03164 1/20 0.47
KDM4E B2RXH2 1/20 0.45
HPGD P15428 3/20 0.43
POLB P06746 1/20 0.43
HTT P42858 1/20 0.43
EPHX2 P34913 1/20 0.43
GRIN2B Q13224 1/20 0.42
HDAC4 P56524 2/20 0.42
HDAC1 Q13547 2/20 0.42
HDAC7 Q8WUI4 2/20 0.42
HDAC11 Q96DB2 2/20 0.42
HDAC8 Q9BY41 2/20 0.42
HDAC6 Q9UBN7 2/20 0.42
HDAC9 Q9UKV0 2/20 0.42
HDAC5 Q9UQL6 2/20 0.42
ALDH1A1 P00352 1/20 0.40
NPC1 O15118 1/20 0.39
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16615844 0.88 EPHX2 (0.51) GRIN2AGRIN1KMT2AKDM4EHPGD
SCHEMBL16615937 0.87 GRIN2A (0.61) GRIN2AGRIN1KMT2AKDM4EHPGD
SCHEMBL16598003 0.84 GRIN2A (0.85) GRIN2AGRIN1KMT2AGRIN2BLMNA
SCHEMBL16615939 0.82 GRIN2A (0.58) GRIN2AGRIN1KMT2AKDM4EHPGD
SCHEMBL16615941 0.82 GRIN2A (0.63) GRIN2AGRIN1KMT2AKDM4EHPGD
SCHEMBL16615944 0.82 GRIN2A (0.59) GRIN2AGRIN1GRIN2B
SCHEMBL16713076 0.81 GRIN2A (0.53) GRIN2AGRIN1KMT2AHPGDPOLB
SCHEMBL16615938 0.80 GRIN2A (0.51) GRIN2AGRIN1GRIN2BALDH1A1
SCHEMBL16598153 0.80 GRIN2A (0.67) GRIN2AGRIN1KMT2AHPGDHTT
SCHEMBL16597898 0.79 GRIN2A (0.55) GRIN2AGRIN1HPGDPOLBGRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9963434-B2 N-arylmethyl sulfonamide negative modulators of NR2A LUC THERAPEUTICS, INC. (US) 2018-05-08 US disclosed
US-9963434-B2 N-arylmethyl sulfonamide negative modulators of NR2A LUC THERAPEUTICS, INC. (US) 2018-05-08 US disclosed
US-20160311782-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A NOVARTIS AG (CH) 2016-10-27 US disclosed
US-20160311782-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A NOVARTIS AG (CH) 2016-10-27 US disclosed
US-20150141433-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A MNEMOSYNE PHARMACEUTICALS, INC. 2015-05-21 US disclosed
US-20150141433-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A MNEMOSYNE PHARMACEUTICALS, INC. 2015-05-21 US disclosed
WO-2015048503-A2 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A MNEMOSYNE PHARMACEUTICALS, INC. (US) 2015-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160311782-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A GRIN2A, GRIN2B, NR2C2 GRIN2A 1/4885GRIN1 5/4885KMT2A 347/4885
US-20150141433-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A GRIN2A, GRIN2B, NR2C2 GRIN2A 1/4885GRIN1 5/4885KMT2A 347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.